ART Advanced Research Technologies Announces 2005 First Quarter Financial Results Conference Call

MONTREAL, May 3 /CNW Telbec/ - ART Advanced Research Technologies Inc.
("ART") (TSX: ARA), a leader in optical molecular imaging products for the
healthcare and pharmaceutical industries, invites you to participate in a
conference call to discuss the company's financial results for the first
quarter ended March 31, 2005. The conference call will follow the press
release issued earlier on the same day, and will be held on:

                         Friday, May 6, 2005
                           8:30 a.m. (EST)

To participate in the conference call when dialing from North America,
please dial (800) 387-6216 (U.S. and Canada). Outside of North America, please
dial (416) 405-9328.  Participants are asked to dial 10 minutes prior to the
start time.

The conference call will feature Micheline Bouchard, President and Chief
Executive Officer, and Jacques BDedard, Chief Financial Officer.
A replay of the conference call will be available from 9:30 (EST), May 6
through May 13. When dialing in for the replay from North America, please dial
(800) 408-3053 or from outside of North America, please dial (416) 695-5800.
The access code for the replay is 3150528(pound sign).
We look forward to your participation and thank you for your interest in
ART Advanced Research Technologies Inc.

About ART

ART Advanced Research Technologies Inc. is a leader in optical molecular
imaging products for the healthcare and pharmaceutical industries. ART has
developed two products based on its innovative technology. The first is
eXplore Optix(TM), a molecular imaging device designed for monitoring
physiological changes in living systems at the preclinical study phases of new
drugs. eXplore Optix(TM) is distributed by GE Healthcare and is used by
industry and academic leaders worldwide to bring new and better treatments to
patients faster. The second is SoftScan(R), a medical imaging device designed
to improve the diagnosis and treatment of breast cancer. ART is
commercializing its products in a global strategic alliance with GE
Healthcare, a world leader in mammography and imaging. ART's shares are listed
on the TSX under the ticker symbol ARA. For more information about ART, visit
the web site at www.art.ca .

This press release may contain forward-looking statements subject to
risks and uncertainties that would cause actual events to differ materially
from expectations. These risks and uncertainties are described in ART Advanced
Research Technologies Inc.'s regulatory filings with Canadian Securities
Commissions and the Securities and Exchange Commission in the United States.